



ABBREVIATED FINANCIAL STATEMENTS

FOR THE PERIOD 01.07.2022 - 30.09.2022

Wroclaw, November 15, 2022



Table of contents

I. SEPARATE STATEMENT OF PROFIT AND LOSS AND OTHER TOTAL INCOME	4
II. SEPARATE STATEMENT OF FINANCIAL SITUATION	5
III. SEPARATE STATEMENT OF CASH FLOWS.....	6
IV. SEPARATE STATEMENT OF CHANGES IN EQUITY CAPITAL.....	7
V. BASIC INFORMATION.....	8
1. Information about the Company.....	8
2. Management Board	8
3. Supervisory Body	8
4. The basis for the preparation of the abbreviated interim financial statement	9
5. Functional currency and presentation currency of the abbreviated interim financial statement.....	9
6. Accounting policy.....	9
7. Information concerning operating segments, geographical areas and key accounts	9
VI. EXPLANATORY NOTES TO THE STATEMENT OF PROFIT AND LOSS AND OTHER TOTAL INCOME	10
1. Revenue from commercial services	10
2. Revenue from grants	10
3. Depreciation and amortisation.....	10
4. Consumption of materials and energy	11
5. Operating costs	11
6. Costs of R&D projects.....	12
VII. EXPLANATORY NOTES TO THE STATEMENT OF FINANCIAL SITUATION	12
1. Tangible assets	12
2. Intangible assets.....	13
3. Long-term financial assets	13
4. Trade and other receivables	14
5. Cash and cash equivalents.....	14
6. Share capital.....	15
7. Lease liabilities.....	16
8. Trade and other liabilities.....	16
9. Subsidies.....	16
VIII. OTHER EXPLANATORY NOTES	17
1. Bank loans and borrowings incurred	17

PURE BIOLOGICS INC.

Abbreviated interim financial statements for 3 months closed on 30 September 2022

2. Contingent assets and liabilities	17
3. Seasonality	17
4. Discontinued operations	17
5. Significant matters in dispute	17
6. Events after the reported period	18
7. Approval of the financial information.....	18

I. SEPARATE STATEMENT OF PROFIT AND LOSS AND OTHER TOTAL INCOME

(in PLN thousand)	Note no	Period of 3 months ended on 30.09.2022	Period of 9 months ended on 30.09.2022	Period of 3 months ended on 30.09.2021	Period of 9 months ended on 30.09.2021
Continued activities					
Revenue from commercial services	1	263	639	82	150
Revenues from grants	2	2 917	9 063	3 065	10 087
Operating revenues		3 179	9 702	3 148	10 237
Depreciation and amortisation	3	614	1 826	665	2 036
Consumption of materials and energy	4	1 353	3 926	1 111	3 298
Rents and leases		487	1 412	745	2 235
Outsourced services		2 092	5 574	852	2 032
Payroll	0	4 078	11 687	3 129	9 218
Social security and other benefits	0	653	1 871	601	1 696
Other costs by kind		251	793	151	408
Total operating expenses	5, 6	9 527	27 088	7 255	20 923
Other operating income			60		1
Other operating expenses		-	1	-	
Operating profit (loss)		(6 347)	(17 327)	(4 107)	(10 684)
Financial revenue	0	36	47	5	18
Financial costs	0	109	1 162	173	405
Gross profit (loss)		(6 420)	(18 443)	(4 276)	(11 072)
Income tax	0	-	-	-	-
Net profit (loss) of continued operations		(6 420)	(18 443)	(4 276)	(11 072)
Discontinued operations					
Profit (loss) of discontinued operations	0	-	-	-	-
Net profit (loss) for the period		(6 420)	(18 443)	(4 276)	(11 072)
Other comprehensive income net					
Other comprehensive income		-	-	-	-
Total income		(6 420)	(18 443)	(4 276)	(11 072)
Profit (loss) per share in PLN		(2,85)	(8,18)	(5,01)	(5,01)
Diluted profit per share in PLN		(2,85)	(8,18)	(4,91)	(4,91)

II. SEPARATE STATEMENT OF FINANCIAL SITUATION

	(in PLN thousand)	Note no	As on 30.09.2022	As on 30.06.2022	As on 31.12.2021	As on 30.09.2021
ASSETS						
Tangible assets		1	4 912	5 077	3 446	3 900
Intangible assets		2	473	570	714	902
Long-term financial assets classified at fair value		3	15	15	15	-
Deferred tax assets			-	-	-	-
Fixed assets			5 400	5 663	4 175	4 802
Reserve			-	-	-	-
Trade and other receivables		4	8 041	10 248	9 290	10 686
Other assets			1 145	462	796	1 083
Cash and cash equivalents		5	15 674	26 922	6 178	39 193
Short-term financial assets classified at fair value			-	-	26 751	-
Assets classified as held for sale			-	-	-	-
Current assets			24 860	37 632	43 015	50 962
ASSETS IN TOTAL			30 260	43 295	47 190	55 764
LIABILITIES						
Share capital		6	225	225	225	225
Supplementary capital		0	74 194	73 082	70 893	69 786
Other reserves			-	-	-	-
Retained profits/Uncovered losses			(31 632)	(31 632)	(19 867)	(19 867)
Current period result			(18 443)	(12 023)	(11 765)	(11 072)
Equity capital in total			24 344	29 652	39 486	39 073
Deferred income tax liabilities			-	-	-	-
Provisions for employee benefits			42	42	42	49
Interest bearing credits and loans			-	-	-	-
Grants settled in time		9	83	93	112	121
Lease liabilities			1 696	2 065	2 000	2 219
Other liabilities			-	-	-	-
Long-term liabilities			1 822	2 200	2 155	2 390
Trade liabilities		8	1 219	1 507	674	952
Current part of interest-bearing credits and loans			-	-	-	-
Lease liabilities			612	583	1 113	1 311
Other liabilities		8	1 170	1 028	20	949
Provisions for employee benefits			62	62	62	512
Reserve for liabilities			-	-	-	-
Grants settled in time		9	1 031	8 263	3 679	10 578
Future terms income			-	-	-	-
Short-term liabilities			4 094	11 443	5 549	14 302
Total liabilities			5 916	13 643	7 704	16 692
LIABILITIES IN TOTAL			30 260	43 295	47 190	55 64

III. SEPARATE STATEMENT OF CASH FLOWS

(in PLN thousand)	Period of 3 months ended on 30.09.2022	Period of 9 months ended on 30.09.2022	Period of 3 months ended on 30.09.2021	Period of 9 months ended on 30.09.2021
OPERATING ACTIVITIES				
Net profit (loss)	(6 420)	(18 443)	(4 276)	(11 072)
Income tax, including:	-	-	-	-
Current income tax	-	-	-	-
Deferred income tax	-	-	-	-
Profit (loss) before tax	(6 420)	(18 443)	(4 276)	(11 072)
Adjustments	(4 062)	6 153	(2 137)	(7 407)
Depreciation and amortisation	614	1 826	665	2 036
Interest expense	109	286	58	184
Management options programme	1 112	3 301	566	1 680
Change in receivables	2 207	1 249	(2 047)	(9 334)
Change in liabilities, excluding credits and loans	(147)	1 695	155	(1 984)
Change in provisions	-	-	-	-
Change in reserves	-	-	-	-
Change in other assets	(683)	(349)	(227)	1 646
Change in grants to be settled	(7 241)	(2 677)	(1 330)	(1 678)
Income tax (paid) refunded	-	-	-	-
Profit (loss) from investment activities	-	811	-	-
Foreign exchange profit (loss)	2	55	-	-
Other adjustments	(35)	(43)	23	42
Net cash flows from operating activities	(10 482)	(12 290)	(6 413)	(18 479)
INVESTMENT ACTIVITIES				
I. Inflows	-	25 984	-	-
Inflows from the sale of tangible and intangible assets	-	50	-	-
Inflows from the sale of participation units	-	25 934	-	-
II. Outflows	352	2 681	270	586
Outflows on tangible and intangible assets	352	2 681	270	586
Net cash flows from investment activities	(352)	23 303	(270)	(586)
FINANCIAL ACTIVITIES				
I. Inflows	-	-	-	52 110
Inflows from the issue of shares	-	-	-	52 110
II. Outflows	414	1 517	690	2 807
Outflows on interest and commissions	109	286	58	184
Payment of liabilities arising from financial leases	305	1 231	632	2 623
Net cash flows from financial activities	(414)	(1 517)	(690)	49 303
TOTAL CASH FLOWS	(11 248)	9 496	(7 372)	30 237
CHANGE IN CASH AND CASH EQUIVALENTS	(11 248)	9 496	(7 372)	30 237
CASH OPENING BALANCE	26 922	6 178	46 566	8 956
CASH CLOSING BALANCE	15 674	15 674	39 193	39 93

IV. SEPARATE STATEMENT OF CHANGES IN EQUITY CAPITAL

(in PLN thousand)	Share capital	Supplementary capital	Retained profits/Uncovered losses	Equity capital in total
As on 1 July 2022	225	73 082	(43 655)	29 652
Profit (loss) for period	-	-	(6 420)	(6 420)
Other total income	-	-	-	-
Total income for the period	-	-	(6 420)	(6 420)
Issue of shares	-	-	-	-
Distribution of the financial result	-	-	-	-
Share-based payments	-	1 112	-	1 112
As on 30 September 2022	225	74 194	(50 075)	24 344

	Share capital	Supplementary capital	Retained profits/Uncovered losses	Equity capital in total
As on 1 January 2022	225	70 893	(31 632)	39 486
Profit (loss) for period	-	-	(18 443)	(18 443)
Other total income	-	-	-	-
Total income for the period	-	-	(18 443)	(18 443)
Issue of shares	-	-	-	-
Distribution of the financial result	-	-	-	-
Share-based payments	-	3 301	-	3 301
As on 30 September 2022	225	74 194	(50 075)	24 344

	Share capital	Supplementary capital	Retained profits/Uncovered losses	Equity capital in total
As on 1 January 2021	165	16 815	(19 867)	(2 887)
Profit (loss) for period	-	-	(11 765)	(11 765)
Other total income	-	-	-	-
Total income for the period	-	-	(11 765)	(11 765)
Issue of shares	60	51 291	-	51 351
Distribution of the financial result	-	-	-	-
Share-based payments	-	2 787	-	2 787
As on 30 December 2021	225	70 893	(31 632)	39 486

	Share capital	Supplementary capital	Retained profits/Uncovered losses	Equity capital in total
As on 1 July 2021	225	69 220	(26 664)	42 782
Profit (loss) for period	-	-	(4 276)	(4 276)
Other total income	-	-	-	-
Total income for the period	-	-	(4 276)	(4 276)
Issue of shares	-	-	-	-
Distribution of the financial result	-	-	-	-
Share-based payments	-	566	-	566
As on 30 September 2021	225	69 786	(30 939)	39 073

V. BASIC INFORMATION

1. Information about the Company

On 30 April 2014 Pure Biologics S.A. (the "Company", "Entity") was entered into the Register of Entrepreneurs of the National Court Register, kept by the Regional Court for Wrocław-Fabryczna in Wrocław, 6th Commercial Division of the National Court Register, under KRS number 0000712811. On 10 January 2018 the conversion of the Entity into a joint-stock company was registered. The Company's registered office is located in Wrocław (54-427), address: ul. Duńska 11. The Entity has been assigned the Tax Identification Number (NIP) number 8943003192 and the Register of National Economy (REGON) number 021305772. The Company maintains a corporate website at www.purebiologics.com and has an e-mail box at info@purebiologics.com.

The Company operates under the provisions of the Commercial Companies Code and the Company's Articles of Association. The duration of the Company is indefinite.

The speciality of Pure Biologics S.A. is research and development in the field of innovative biological drugs and medical devices with therapeutic and diagnostic use. The Company also conducts contract research for pharmaceutical and biotechnological companies, especially in the field of active molecules' selection (antibodies and aptamers) for medical use (therapeutic drugs and procedures, diagnostics) and production, purifying and analysis of recombinant proteins and the development of measurement methods.

2. Management Board

As on 30 September 2022 and the day of the issue of this report the Board consists of:

- Mr Filip Jeleń – President of the Management Board,
- Mr Romuald Harwas – Vice-President of the Management Board,
- Mr Petrus Spee – Vice-President of the Management Board.

3. Supervisory Body

As on 31 March 2022 and as on the date of this report, the Supervisory Body consists of:

- Mr Andrzej Trznadel – Chairman of the Supervisory Body,
- Mr Tadeusz Wesołowski – Deputy Chairman of the Supervisory Body,
- Ms Julia Bar – Member of the Supervisory Body,
- Mr Andrzej Kierzkowski – Member of the Supervisory Body,
- Mr Mariusz Czekąła – Member of the Supervisory Body.

Audit Committee

As from 29.07.2020 the Company has an Audit Committee consisting of:

- Mr Mariusz Czekąła – Chairman of the Audit Committee,
- Ms Julia Bar – Member of the Audit Committee
- Mr Andrzej Trznadel – Member of the Audit Committee.

Mr Mariusz Czekąła is a member of the Audit Committee who fulfils the conditions of the Act on Statutory Auditors concerning having knowledge and skills in accounting or auditing, while Ms Julia

Bar has knowledge of the industry in which the Company operates. Julia Bar and Mariusz Czekala are also the independent members within the meaning of the Act on Statutory Auditors.

4. The basis for the preparation of the abbreviated interim financial statement

This abbreviated interim financial statement has been prepared in accordance with the International Financial Reporting Standards (MSSF) and, in particular, in accordance with the International Accounting Standard No. 34 and MSSF approved by the European Union, and in the scope not regulated in these Standards in accordance with the requirements of the Act on Accounting of 29 September 1994 and regulations issued on its basis.

The abbreviated interim financial statement presents the Company's financial position as on 30 September 2022, the results of its operations and its cash flows for the three months ended 30 September 2022.

The abbreviated interim financial statement has been prepared with assumption of continuation of the Company's economic activity in foreseeable future. As on the day of approval of this abbreviated interim financial statement, the Management Board does not find any circumstances implying any threats to the continuation of the Entity's activity. The duration of the Company is indefinite.

The abbreviated interim financial statement, except for the Statement on Cash Flows, has been prepared in accordance with accrual method.

5. Functional currency and presentation currency of the abbreviated interim financial statement

Functional currency and presentation currency of the abbreviated interim financial report is Polish Zloty (PLN). The data is shown in PLN thousand, unless stated otherwise.

6. Accounting policy

Selected significant accounting policies and significant values based on judgements and estimates are presented and described in the Separate Financial Statements for the financial year ended 31.12.2021, which have been made public and can be found at <https://purebiologics.com/pl/periodic-report/raport-espi-rr-2021-raport-roczny-za-rok-obrotowy-2021/>. The Company applied the accounting principles in a continuous manner for all presented reporting periods.

7. Information concerning operating segments, geographical areas and key accounts

Based on the definition of operating segments in IFRS 8 'Operating Segments', the Company operates within a single market, defined as 'Biotechnology Innovation'. Revenues are divided into commercial service revenues or grant revenues. Management, however, does not measure operational performance in detail on the basis of any of these categories. Accordingly, the Company's activities are presented within a single operating segment.

VI. EXPLANATORY NOTES TO THE STATEMENT OF PROFIT AND LOSS AND OTHER TOTAL INCOME

1. Revenue from commercial services

Material structure of revenues from continued operations in the third quarter of 2022 and in the comparable period is as follows:

	Period of 3 months ended on 30.09.2022	Period of 9 months ended on 30.09.2022	Period of 3 months ended on 30.09.2021	Period of 9 months ended on 30.09.2021
Revenue from sales of services, including:	262	629	74	139
domestic sales	44	255	10	31
export sales	218	374	64	108
Revenue from other sales, including:	1	10	8	11
domestic sales	1	10	3	6
export sales	-	-	5	5
	263	639	82	150

2. Revenue from grants

Revenue from grants recognised by the Company

	Period of 3 months ended on 30.09.2022	Period of 9 months ended on 30.09.2022	Period of 3 months ended on 30.09.2021	Period of 9 months ended on 30.09.2021
PB001 MutliBody	171	680	289	1 321
PB002 AptaPheresis	207	640	275	964
PB003 PureActivator	1 206	3 414	1 035	2 551
PB004 PureBIKE	797	2 622	871	2 921
PB005 Apta-MG	476	1 476	547	1 708
PB006 AptaMLN	3	10	29	518
PB007 MARA	-	-	-	-
PB008 MAGBBRIS	-	96	-	54
PB013 Altercar	17	55	18	50
PB014 DualDrug	40	71	-	-
Other	-	-	-	-
Total revenue from grants	2 917	9 063	3 065	10 087

In the Company, there are mainly subsidies to the expenses, i.e. to the conducted research works.

3. Depreciation and amortisation

Depreciation and amortisation in the reported period was as follows:

PURE BIOLOGICS INC.

Abbreviated interim financial statements for 3 months closed on 30 September 2022

	Period of 3 months ended on 30.09.2022	Period of 9 months ended on 30.09.2021	Period of 3 months ended on 30.09.2021	Period of 9 months ended on 30.09.2021
Depreciation and amortisation of tangible assets	517	1 533	567	1 736
own	139	315	36	94
used under rental or lease agreements	378	1 218	531	1 642
Depreciation and amortisation of intangible assets	97	292	98	300
own	85	255	85	248
used under rental or lease agreements	13	38	13	52
Total depreciation and amortisation	614	1 826	665	2 036

4. Consumption of materials and energy

The material and energy consumption in the reported period was as follows:

	Period of 3 months ended on 30.09.2022	Period of 9 months ended on 30.09.2022	Period of 3 months ended on 30.09.2021	Period of 9 months ended on 30.09.2021
Reagents	999	2 718	690	1 961
Laboratory supplies	228	686	253	976
Small laboratory appliances and equipment	84	365	117	263
Other materials and energy	43	157	51	97
Consumption of materials and energy	1 353	3 926	1 111	3 298

5. Operating costs

Operating costs incurred by the Company in the reported period were as follows:

	Period of 3 months ended on 30.09.2022	Period of 9 months ended on 30.09.2022	Period of 3 months ended on 30.09.2021	Period of 9 months ended on 30.09.2021
Costs of general administration and sales	2 176	10 010	1 496	4 141
Costs of sales	47	165	53	112
Costs of R&D projects	7 304	16 913	5 705	16 669
Costs of finished projects	-	-	-	-
TOTAL	9 527	27 088	7 255	20 923

6. Costs of R&D projects

Costs incurred on R&D projects in reported period were as follows:

	Period of 3 months ended on 30.09.2022	Period of 9 months ended on 30.09.2022	Period of 3 months ended on 30.09.2021	Period of 9 months ended on 30.09.2021
PB001 MutliBody	428	1 147	534	2 121
PB002 AptaPheresis	571	1 427	680	1 584
PB003 PureActivator	2 652	5 580	1 696	4 585
PB004 PureBIKE	2 260	5 431	1 483	4 585
PB005 Apta-MG	957	2 347	927	2 691
PB006 AptaMLN	73	242	67	817
PB008 MAGBRRIS	-	-	3	85
PB013 Altercar	33	79	32	81
PB014 DualDrug	65	106	-	-
Other projects	-	-	282	420
Total costs of subsidised projects	7 039	16 359	5 705	16 967
Unsubsidised projects	264	554	-	-
Total costs of R&D projects	7 304	16 913	5 705	16 967

VII. EXPLANATORY NOTES TO THE STATEMENT OF FINANCIAL SITUATION

1. Tangible assets

Specification of tangible fixed assets.

	As on 30.09.2022	As on 30.06.2022	As on 31.12.2021	As on 30.09.2021
Land and buildings	-	19	76	104
Machinery and equipment	4 523	4 624	3 265	3 770
Means of transport	350	392	93	15
Others	39	43	12	11
Total	4 912	5 077	3 446	3 900

Ownership structure of tangible fixed assets.

	As on 30.09.2022	As on 30.06.2022	As on 31.12.2021	As on 30.09.2021
Own	2 868	2 655	553	563
Used under rental or lease agreements MSSF 16	2 044	2 423	2 893	3 337
Total	4 912	5 077	3 446	3 900

During the period covered by the report, the Company purchased its own fixed assets with a gross value of PLN 2,716,354.76 (net value as at 30.09.2022 amounted to PLN 2,495,838.62) and acquired fixed assets worth PLN 369,238.06 (net value as at 30.09.2022 amounted to PLN 303,414.84) through long-term rental, lease or leasing agreements.

2. Intangible assets

Specification of intangible assets.

	<u>As on</u> <u>30.09.2022</u>	<u>As on</u> <u>30.06.2022</u>	<u>As on</u> <u>31.12.2021</u>	<u>As on</u> <u>30.09.2021</u>
Costs of finished development works	182	249	384	626
Patents and licenses	270	197	202	92
Other	21	124	128	184
Total	473	570	714	902

Ownership structure of intangible assets.

	<u>As on</u> <u>30.09.2022</u>	<u>As on</u> <u>30.06.2022</u>	<u>As on</u> <u>31.12.2021</u>	<u>As on</u> <u>30.09.2021</u>
Own	431	516	634	810
Used under rental or lease agreements MSSF 16	42	54	80	92
Total	473	570	714	902

In the reported period there were no significant transactions of acquisition or sale of intangible assets.

3. Long-term financial assets

	<u>As on</u> <u>30.09.2022</u>	<u>As on</u> <u>30.06.2022</u>	<u>As on</u> <u>31.12.2021</u>	<u>As on</u> <u>30.09.2021</u>
Long-term financial assets measured at fair value, of which:	-	-	-	-
- shares in ProAnimali Sp. z o.o.	15	15	15	-
Total	15	15	15	-

4. Trade and other receivables

The structure of trade and other receivables on 30 September 2022 was as follows.

	<u>As on</u> <u>30.09.2022</u>	<u>As on</u> <u>30.06.2022</u>	<u>As on</u> <u>31.12.2021</u>	<u>As on</u> <u>30.09.2021</u>
Trade and other receivables	1 854	1 493	53	11
Including affiliates	-	-	-	-
Receivables from subsidies due	5 246	7 161	6 411	8 517
Budget receivables (including VAT to be refunded on acquired assets)	910	1 569	2 809	2 114
Other receivables from third parties	32	25	17	45
Including affiliates	-	-	-	-
Total receivables (net)	8 041	10 248	9 290	10 686
Receivables write-down	-	-	-	-
Gross receivables	8 041	10 248	9 290	10 686

During the period covered by this report, the Company did not write down any receivables. As on 30.09.2022. The Company had receivables only in the Polish currency.

5. Cash and cash equivalents

Structure of cash and cash equivalents at the end of the period covered by the abbreviated interim financial statement.

	<u>As on</u> <u>30.09.2022</u>	<u>As on</u> <u>30.06.2022</u>	<u>As on</u> <u>31.12.2021</u>	<u>As on</u> <u>30.09.2021</u>
Cash in hand	-	-	-	-
Cash in bank accounts	3 864	26 922	6 178	9 193
Deposits	11 810	-	-	30 000
Total	15 674	26 922	6 178	39 193

Cash and cash equivalents according to currency.

	<u>As on</u> <u>30.09.2022</u>	<u>As on</u> <u>30.06.2022</u>	<u>As on</u> <u>31.12.2021</u>	<u>As on</u> <u>30.09.2021</u>
PLN	14 262	23 797	6 163	39 188
EUR	589	875	15	5
USD	-	887	-	-
GBP	824	1 362	-	-
Total	15 674	26 922	6 178	39 193

The Company had no restricted cash during the period covered by the abbreviated interim financial statement.

6. Share capital

The number of shares at the date of this abbreviated interim financial statement was as follows.

	<u>As on 30.09.2022</u>	<u>As on 30.06.2022</u>	<u>As on 31.12.2021</u>	<u>As on 30.09.2021</u>
A series	185 400	185 400	185 400	185 400
B1 series	296 500	296 500	296 500	296 500
B2 series	544 100	544 100	544 100	544 100
C series	146 410	146 410	146 410	146 410
D series	481 590	481 590	481 590	481 590
E series	600 000	600 000	600 000	600 000
Total	<u>2 254 000</u>	<u>2 254 000</u>	<u>2 254 000</u>	<u>2 254 000</u>

Nominal share price: PLN 0,10.

Shareholding structure (number of shares) as on the day ending the reporting period.

	<u>As on 30.09.2022</u>	<u>As on 30.06.2022</u>	<u>As on 31.12.2021</u>	<u>As on 30.09.2021</u>
TFI Allianz Polska S.A.	302 298	BD	BD	BD
Filip Jeleń	257 817	398 603	398 603	398 603
Aviva investors Poland TFI S.A.	-	170 464	170 464	170 464
Maciej Mazurek	160 104	160 104	160 104	160 104
Augebit FIZ	153 220	153 220	153 220	153 220
Piotr Jakimowicz	146 576	146 576	146 576	146 576
Other	1 233 985	1 225 033	1 225 033	1 225 033
Total	<u>2 254 000</u>	<u>2 254 000</u>	<u>2 254 000</u>	<u>2 254 000</u>

Shareholding structure (number of shares) as on the day ending the reporting period.

	<u>As on 30.09.2022</u>	<u>As on 30.06.2022</u>	<u>As on 31.12.2021</u>	<u>As on 30.09.2021</u>
TFI Allianz Polska S.A.	13,41%	BD	BD	BD
Filip Jeleń	11,44%	17,68%	17,68%	17,68%
Aviva investors Poland TFI S.A.	0,00%	7,56%	7,56%	7,56%
Maciej Mazurek	7,10%	7,10%	7,10%	7,10%
Augebit FIZ	6,80%	6,80%	6,80%	6,80%
Piotr Jakimowicz	6,50%	6,50%	6,50%	6,50%
Other	54,75%	54,35%	54,35%	54,35%
Total	<u>100,00%</u>	<u>100,00%</u>	<u>100,00%</u>	<u>100,00%</u>

In the reported period dividends paid and proposed for payment did not occur.

7. Lease liabilities

Specification of lease liabilities as on the day ending the reporting period.

	<u>As on 30.09.2022</u>	<u>As on 30.06.2022</u>	<u>As on 31.12.2021</u>	<u>As on 30.09.2021</u>
Long-term	1 696	2 065	2 000	2 219
Short-term	612	583	1 113	1 311
Total	<u>2 308</u>	<u>2 648</u>	<u>3 114</u>	<u>3 530</u>

During the period covered by the report, the Company entered into long-term lease, tenancy or rental agreements with a value of PLN 369,238.06.

8. Trade and other liabilities

Specification of trade and other liabilities as on the day ending the reporting period.

	<u>As on 30.09.2022</u>	<u>As on 30.06.2022</u>	<u>As on 31.12.2021</u>	<u>As on 30.09.2021</u>
Trade liabilities	1 219	1 507	674	952
Public law liabilities, including	445	351	19	307
personal income tax	104	77	3	105
social security	327	261	3	193
State Fund for the Rehabilitation of the Disabled	14	14	13	12
Employee Capital Plans	-	-	-	(3)
Salary liabilities	721	677	-	622
Other liabilities	4	-	-	20
TOTAL:	<u>2 389</u>	<u>2 536</u>	<u>694</u>	<u>1 901</u>

9. Subsidies

Subsidy specification as on the day ending the reporting period.

	<u>As on 30.09.2022</u>	<u>As on 30.06.2022</u>	<u>As on 31.12.2021</u>	<u>As on 30.09.2021</u>
Long-term, including	83	93	112	121
development subsidies	83	93	112	121
advances for research and development	-	-	-	-
Short-term, including	1 031	8 263	3 679	10 578
development subsidies	-	-	-	314
advances for research and development	1 031	8 263	3 679	10 264
Total	<u>1 114</u>	<u>8 355</u>	<u>3 791</u>	<u>10 700</u>

The state of advances for research and development according to ongoing projects as on the day ending the reported period.

PURE BIOLOGICS INC.

Abbreviated interim financial statements for 3 months closed on 30 September 2022

	As on 30.09.2022	As on 30.06.2022	As on 31.12.2021	As on 30.09.2021
Long-term	83	93	112	121
PB012 PureApta – Finished development	83	93	112	121
PB010 PureSelect2 – Finished development	-	-	-	-
Short-term	1 031	8 263	3 679	10 578
PB001 MutliBody	113	5 326	1 489	3 062
PB002 AptaPheresis	659	2 336	363	1 044
PB003 PureActivator	(40)	303	-	1 443
PB004 PureBIKE	220	387	1 827	3 148
PB005 Apta-MG	145	48	-	525
PB006 AptaMLN	(1)	(1)	-	442
PB007 MARA	-	-	-	597
PB008 MAGBRRIS	-	-	-	27
PB010 PureSelect2	-	-	-	314
PB013 Altecar	(68)	(106)	-	(50)
PB014 Dualdrug	2	(31)	-	-
Other	-	-	-	25
Total	1 114	8 355	3 791	10 700

VIII. OTHER EXPLANATORY NOTES

1. Bank loans and borrowings incurred

In the reported period loans and borrowings incurred did not occur.

2. Contingent assets and liabilities

In the reported period contingent assets did not occur.

3. Seasonality

In the field of activity in which the Company operates, the seasonality does not occur.

4. Discontinued operations

Discontinued operations did not occur in the reported period.

5. Significant matters in dispute

In the reported period and on the day of the issue of the abbreviated interim financial statement there have been no significant litigation against the Company, which could have influenced or have influenced in the past on the Company's financial situation and operating results.

6. Events after the reported period

Between the balance date and the day of preparation of the abbreviated interim financial statement the significant events did not occur.

7. Approval of the financial information

This abbreviated interim financial statement was approved for publication by the Management Board of the Company on 15 November 2022.

Filip Jan Jeleń	Romuald Apollo Harwas	Petrus Johannes Louis Spee
President of the Management Board	Vice-President of the Management Board	Vice-President of the Management Board

Brygida Rusinek
Person responsible for drawing up the
abbreviated interim financial statement

Wrocław, 15 November 2022.